Tapewire

Nasdaq · USD

OPK

OPKO HEALTH, INC.

Export transactions ↓
Tapewire entity
4891
SEC CIK
0000944809
Parsed reports
659

Last 12 months

Inside the activity.

33 purchase rows · 0 sale rows

Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.
Monthly counts
MonthPurchasesSales
Nov 2025320
Dec 202500
Jan 202600
Feb 202600
Mar 202610
Apr 202600
May 202600
Jun 202600
Jul 202600
Aug 202600
Sep 202600
Oct 202600

Latest available

Insider transactions

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateOwner / reported roleActivity / securityShares / unitsReported priceReported valueDetails
August 05, 2022 Filed Aug 8, 2022 12:05 UTC
FROST PHILLIP MD ET ALDirector · CEO & Chairman · 10% owner
PurchaseCommon Stock 7,003 $2.32 $16,246.96
Disclosure

SEC source: 0001209191-22-044703 · doc4.xml · nonDerivative · entry 23

FROST PHILLIP MD ET AL · CIK 0000898860 · Director · CEO & Chairman · 10% owner

Frost Gamma Investments Trust · CIK 0001380896 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 196,956,694

F1 · ownership.nature: The securities are held by Frost Gamma Investments Trust, of which Phillip Frost M.D., is the trustee. Frost Gamma L.P. is the sole and exclusive beneficiary of Frost Gamma Investments Trust. Dr. Frost is one of two limited partners of Frost Gamma L.P. The general partner of Frost Gamma L.P. is Frost Gamma, Inc., and the sole shareholder of Frost Gamma, Inc. is Frost-Nevada Corporation. Dr. Frost is also the sole shareholder of Frost-Nevada Corporation. The reporting person disclaims beneficial ownership of these securities, except to the extent of any pecuniary interest therein and this report shall not be deemed an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

Read SEC document
August 05, 2022 Filed Aug 8, 2022 12:05 UTC
FROST PHILLIP MD ET ALDirector · CEO & Chairman · 10% owner
PurchaseCommon Stock 43,656 $2.32 $101,063.64
Disclosure

SEC source: 0001209191-22-044703 · doc4.xml · nonDerivative · entry 22

FROST PHILLIP MD ET AL · CIK 0000898860 · Director · CEO & Chairman · 10% owner

Frost Gamma Investments Trust · CIK 0001380896 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 196,949,691

F1 · ownership.nature: The securities are held by Frost Gamma Investments Trust, of which Phillip Frost M.D., is the trustee. Frost Gamma L.P. is the sole and exclusive beneficiary of Frost Gamma Investments Trust. Dr. Frost is one of two limited partners of Frost Gamma L.P. The general partner of Frost Gamma L.P. is Frost Gamma, Inc., and the sole shareholder of Frost Gamma, Inc. is Frost-Nevada Corporation. Dr. Frost is also the sole shareholder of Frost-Nevada Corporation. The reporting person disclaims beneficial ownership of these securities, except to the extent of any pecuniary interest therein and this report shall not be deemed an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

Read SEC document
August 05, 2022 Filed Aug 8, 2022 12:05 UTC
FROST PHILLIP MD ET ALDirector · CEO & Chairman · 10% owner
PurchaseCommon Stock 804 $2.31 $1,857.24
Disclosure

SEC source: 0001209191-22-044703 · doc4.xml · nonDerivative · entry 21

FROST PHILLIP MD ET AL · CIK 0000898860 · Director · CEO & Chairman · 10% owner

Frost Gamma Investments Trust · CIK 0001380896 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 196,906,035

F1 · ownership.nature: The securities are held by Frost Gamma Investments Trust, of which Phillip Frost M.D., is the trustee. Frost Gamma L.P. is the sole and exclusive beneficiary of Frost Gamma Investments Trust. Dr. Frost is one of two limited partners of Frost Gamma L.P. The general partner of Frost Gamma L.P. is Frost Gamma, Inc., and the sole shareholder of Frost Gamma, Inc. is Frost-Nevada Corporation. Dr. Frost is also the sole shareholder of Frost-Nevada Corporation. The reporting person disclaims beneficial ownership of these securities, except to the extent of any pecuniary interest therein and this report shall not be deemed an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

Read SEC document
August 05, 2022 Filed Aug 8, 2022 12:05 UTC
FROST PHILLIP MD ET ALDirector · CEO & Chairman · 10% owner
PurchaseCommon Stock 11,375 $2.31 $26,219.38
Disclosure

SEC source: 0001209191-22-044703 · doc4.xml · nonDerivative · entry 20

FROST PHILLIP MD ET AL · CIK 0000898860 · Director · CEO & Chairman · 10% owner

Frost Gamma Investments Trust · CIK 0001380896 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 196,905,231

F1 · ownership.nature: The securities are held by Frost Gamma Investments Trust, of which Phillip Frost M.D., is the trustee. Frost Gamma L.P. is the sole and exclusive beneficiary of Frost Gamma Investments Trust. Dr. Frost is one of two limited partners of Frost Gamma L.P. The general partner of Frost Gamma L.P. is Frost Gamma, Inc., and the sole shareholder of Frost Gamma, Inc. is Frost-Nevada Corporation. Dr. Frost is also the sole shareholder of Frost-Nevada Corporation. The reporting person disclaims beneficial ownership of these securities, except to the extent of any pecuniary interest therein and this report shall not be deemed an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

Read SEC document
August 05, 2022 Filed Aug 8, 2022 12:05 UTC
FROST PHILLIP MD ET ALDirector · CEO & Chairman · 10% owner
PurchaseCommon Stock 69,986 $2.30 $160,967.80
Disclosure

SEC source: 0001209191-22-044703 · doc4.xml · nonDerivative · entry 19

FROST PHILLIP MD ET AL · CIK 0000898860 · Director · CEO & Chairman · 10% owner

Frost Gamma Investments Trust · CIK 0001380896 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 196,893,856

F1 · ownership.nature: The securities are held by Frost Gamma Investments Trust, of which Phillip Frost M.D., is the trustee. Frost Gamma L.P. is the sole and exclusive beneficiary of Frost Gamma Investments Trust. Dr. Frost is one of two limited partners of Frost Gamma L.P. The general partner of Frost Gamma L.P. is Frost Gamma, Inc., and the sole shareholder of Frost Gamma, Inc. is Frost-Nevada Corporation. Dr. Frost is also the sole shareholder of Frost-Nevada Corporation. The reporting person disclaims beneficial ownership of these securities, except to the extent of any pecuniary interest therein and this report shall not be deemed an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

Read SEC document
August 05, 2022 Filed Aug 8, 2022 12:05 UTC
FROST PHILLIP MD ET ALDirector · CEO & Chairman · 10% owner
PurchaseCommon Stock 3,500 $2.30 $8,046.50
Disclosure

SEC source: 0001209191-22-044703 · doc4.xml · nonDerivative · entry 18

FROST PHILLIP MD ET AL · CIK 0000898860 · Director · CEO & Chairman · 10% owner

Frost Gamma Investments Trust · CIK 0001380896 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 196,823,870

F1 · ownership.nature: The securities are held by Frost Gamma Investments Trust, of which Phillip Frost M.D., is the trustee. Frost Gamma L.P. is the sole and exclusive beneficiary of Frost Gamma Investments Trust. Dr. Frost is one of two limited partners of Frost Gamma L.P. The general partner of Frost Gamma L.P. is Frost Gamma, Inc., and the sole shareholder of Frost Gamma, Inc. is Frost-Nevada Corporation. Dr. Frost is also the sole shareholder of Frost-Nevada Corporation. The reporting person disclaims beneficial ownership of these securities, except to the extent of any pecuniary interest therein and this report shall not be deemed an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

Read SEC document
August 05, 2022 Filed Aug 8, 2022 12:05 UTC
FROST PHILLIP MD ET ALDirector · CEO & Chairman · 10% owner
PurchaseCommon Stock 2,364 $2.30 $5,433.42
Disclosure

SEC source: 0001209191-22-044703 · doc4.xml · nonDerivative · entry 17

FROST PHILLIP MD ET AL · CIK 0000898860 · Director · CEO & Chairman · 10% owner

Frost Gamma Investments Trust · CIK 0001380896 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 196,820,370

F1 · ownership.nature: The securities are held by Frost Gamma Investments Trust, of which Phillip Frost M.D., is the trustee. Frost Gamma L.P. is the sole and exclusive beneficiary of Frost Gamma Investments Trust. Dr. Frost is one of two limited partners of Frost Gamma L.P. The general partner of Frost Gamma L.P. is Frost Gamma, Inc., and the sole shareholder of Frost Gamma, Inc. is Frost-Nevada Corporation. Dr. Frost is also the sole shareholder of Frost-Nevada Corporation. The reporting person disclaims beneficial ownership of these securities, except to the extent of any pecuniary interest therein and this report shall not be deemed an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

Read SEC document
August 05, 2022 Filed Aug 8, 2022 12:05 UTC
FROST PHILLIP MD ET ALDirector · CEO & Chairman · 10% owner
PurchaseCommon Stock 600 $2.30 $1,378.50
Disclosure

SEC source: 0001209191-22-044703 · doc4.xml · nonDerivative · entry 16

FROST PHILLIP MD ET AL · CIK 0000898860 · Director · CEO & Chairman · 10% owner

Frost Gamma Investments Trust · CIK 0001380896 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 196,818,006

F1 · ownership.nature: The securities are held by Frost Gamma Investments Trust, of which Phillip Frost M.D., is the trustee. Frost Gamma L.P. is the sole and exclusive beneficiary of Frost Gamma Investments Trust. Dr. Frost is one of two limited partners of Frost Gamma L.P. The general partner of Frost Gamma L.P. is Frost Gamma, Inc., and the sole shareholder of Frost Gamma, Inc. is Frost-Nevada Corporation. Dr. Frost is also the sole shareholder of Frost-Nevada Corporation. The reporting person disclaims beneficial ownership of these securities, except to the extent of any pecuniary interest therein and this report shall not be deemed an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

Read SEC document
August 05, 2022 Filed Aug 8, 2022 12:05 UTC
FROST PHILLIP MD ET ALDirector · CEO & Chairman · 10% owner
PurchaseCommon Stock 52,210 $2.30 $119,821.95
Disclosure

SEC source: 0001209191-22-044703 · doc4.xml · nonDerivative · entry 15

FROST PHILLIP MD ET AL · CIK 0000898860 · Director · CEO & Chairman · 10% owner

Frost Gamma Investments Trust · CIK 0001380896 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 196,817,406

F1 · ownership.nature: The securities are held by Frost Gamma Investments Trust, of which Phillip Frost M.D., is the trustee. Frost Gamma L.P. is the sole and exclusive beneficiary of Frost Gamma Investments Trust. Dr. Frost is one of two limited partners of Frost Gamma L.P. The general partner of Frost Gamma L.P. is Frost Gamma, Inc., and the sole shareholder of Frost Gamma, Inc. is Frost-Nevada Corporation. Dr. Frost is also the sole shareholder of Frost-Nevada Corporation. The reporting person disclaims beneficial ownership of these securities, except to the extent of any pecuniary interest therein and this report shall not be deemed an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

Read SEC document
August 05, 2022 Filed Aug 8, 2022 12:05 UTC
FROST PHILLIP MD ET ALDirector · CEO & Chairman · 10% owner
PurchaseCommon Stock 24,400 $2.29 $55,876.00
Disclosure

SEC source: 0001209191-22-044703 · doc4.xml · nonDerivative · entry 14

FROST PHILLIP MD ET AL · CIK 0000898860 · Director · CEO & Chairman · 10% owner

Frost Gamma Investments Trust · CIK 0001380896 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 196,765,196

F1 · ownership.nature: The securities are held by Frost Gamma Investments Trust, of which Phillip Frost M.D., is the trustee. Frost Gamma L.P. is the sole and exclusive beneficiary of Frost Gamma Investments Trust. Dr. Frost is one of two limited partners of Frost Gamma L.P. The general partner of Frost Gamma L.P. is Frost Gamma, Inc., and the sole shareholder of Frost Gamma, Inc. is Frost-Nevada Corporation. Dr. Frost is also the sole shareholder of Frost-Nevada Corporation. The reporting person disclaims beneficial ownership of these securities, except to the extent of any pecuniary interest therein and this report shall not be deemed an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

Read SEC document
August 05, 2022 Filed Aug 8, 2022 12:05 UTC
FROST PHILLIP MD ET ALDirector · CEO & Chairman · 10% owner
PurchaseCommon Stock 35,734 $2.29 $81,652.19
Disclosure

SEC source: 0001209191-22-044703 · doc4.xml · nonDerivative · entry 13

FROST PHILLIP MD ET AL · CIK 0000898860 · Director · CEO & Chairman · 10% owner

Frost Gamma Investments Trust · CIK 0001380896 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 196,740,796

F1 · ownership.nature: The securities are held by Frost Gamma Investments Trust, of which Phillip Frost M.D., is the trustee. Frost Gamma L.P. is the sole and exclusive beneficiary of Frost Gamma Investments Trust. Dr. Frost is one of two limited partners of Frost Gamma L.P. The general partner of Frost Gamma L.P. is Frost Gamma, Inc., and the sole shareholder of Frost Gamma, Inc. is Frost-Nevada Corporation. Dr. Frost is also the sole shareholder of Frost-Nevada Corporation. The reporting person disclaims beneficial ownership of these securities, except to the extent of any pecuniary interest therein and this report shall not be deemed an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

Read SEC document
August 05, 2022 Filed Aug 8, 2022 12:05 UTC
FROST PHILLIP MD ET ALDirector · CEO & Chairman · 10% owner
PurchaseCommon Stock 27,700 $2.28 $63,156.00
Disclosure

SEC source: 0001209191-22-044703 · doc4.xml · nonDerivative · entry 12

FROST PHILLIP MD ET AL · CIK 0000898860 · Director · CEO & Chairman · 10% owner

Frost Gamma Investments Trust · CIK 0001380896 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 196,705,062

F1 · ownership.nature: The securities are held by Frost Gamma Investments Trust, of which Phillip Frost M.D., is the trustee. Frost Gamma L.P. is the sole and exclusive beneficiary of Frost Gamma Investments Trust. Dr. Frost is one of two limited partners of Frost Gamma L.P. The general partner of Frost Gamma L.P. is Frost Gamma, Inc., and the sole shareholder of Frost Gamma, Inc. is Frost-Nevada Corporation. Dr. Frost is also the sole shareholder of Frost-Nevada Corporation. The reporting person disclaims beneficial ownership of these securities, except to the extent of any pecuniary interest therein and this report shall not be deemed an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

Read SEC document
August 05, 2022 Filed Aug 8, 2022 12:05 UTC
FROST PHILLIP MD ET ALDirector · CEO & Chairman · 10% owner
PurchaseCommon Stock 49,249 $2.28 $112,041.48
Disclosure

SEC source: 0001209191-22-044703 · doc4.xml · nonDerivative · entry 11

FROST PHILLIP MD ET AL · CIK 0000898860 · Director · CEO & Chairman · 10% owner

Frost Gamma Investments Trust · CIK 0001380896 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 196,677,362

F1 · ownership.nature: The securities are held by Frost Gamma Investments Trust, of which Phillip Frost M.D., is the trustee. Frost Gamma L.P. is the sole and exclusive beneficiary of Frost Gamma Investments Trust. Dr. Frost is one of two limited partners of Frost Gamma L.P. The general partner of Frost Gamma L.P. is Frost Gamma, Inc., and the sole shareholder of Frost Gamma, Inc. is Frost-Nevada Corporation. Dr. Frost is also the sole shareholder of Frost-Nevada Corporation. The reporting person disclaims beneficial ownership of these securities, except to the extent of any pecuniary interest therein and this report shall not be deemed an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

Read SEC document
August 05, 2022 Filed Aug 8, 2022 12:05 UTC
FROST PHILLIP MD ET ALDirector · CEO & Chairman · 10% owner
PurchaseCommon Stock 500 $2.27 $1,136.25
Disclosure

SEC source: 0001209191-22-044703 · doc4.xml · nonDerivative · entry 10

FROST PHILLIP MD ET AL · CIK 0000898860 · Director · CEO & Chairman · 10% owner

Frost Gamma Investments Trust · CIK 0001380896 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 196,628,113

F1 · ownership.nature: The securities are held by Frost Gamma Investments Trust, of which Phillip Frost M.D., is the trustee. Frost Gamma L.P. is the sole and exclusive beneficiary of Frost Gamma Investments Trust. Dr. Frost is one of two limited partners of Frost Gamma L.P. The general partner of Frost Gamma L.P. is Frost Gamma, Inc., and the sole shareholder of Frost Gamma, Inc. is Frost-Nevada Corporation. Dr. Frost is also the sole shareholder of Frost-Nevada Corporation. The reporting person disclaims beneficial ownership of these securities, except to the extent of any pecuniary interest therein and this report shall not be deemed an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

Read SEC document
August 05, 2022 Filed Aug 8, 2022 12:05 UTC
FROST PHILLIP MD ET ALDirector · CEO & Chairman · 10% owner
PurchaseCommon Stock 300 $2.27 $681.03
Disclosure

SEC source: 0001209191-22-044703 · doc4.xml · nonDerivative · entry 9

FROST PHILLIP MD ET AL · CIK 0000898860 · Director · CEO & Chairman · 10% owner

Frost Gamma Investments Trust · CIK 0001380896 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 196,627,613

F1 · ownership.nature: The securities are held by Frost Gamma Investments Trust, of which Phillip Frost M.D., is the trustee. Frost Gamma L.P. is the sole and exclusive beneficiary of Frost Gamma Investments Trust. Dr. Frost is one of two limited partners of Frost Gamma L.P. The general partner of Frost Gamma L.P. is Frost Gamma, Inc., and the sole shareholder of Frost Gamma, Inc. is Frost-Nevada Corporation. Dr. Frost is also the sole shareholder of Frost-Nevada Corporation. The reporting person disclaims beneficial ownership of these securities, except to the extent of any pecuniary interest therein and this report shall not be deemed an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

Read SEC document
August 05, 2022 Filed Aug 8, 2022 12:05 UTC
FROST PHILLIP MD ET ALDirector · CEO & Chairman · 10% owner
PurchaseCommon Stock 400 $2.27 $908.00
Disclosure

SEC source: 0001209191-22-044703 · doc4.xml · nonDerivative · entry 8

FROST PHILLIP MD ET AL · CIK 0000898860 · Director · CEO & Chairman · 10% owner

Frost Gamma Investments Trust · CIK 0001380896 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 196,627,313

F1 · ownership.nature: The securities are held by Frost Gamma Investments Trust, of which Phillip Frost M.D., is the trustee. Frost Gamma L.P. is the sole and exclusive beneficiary of Frost Gamma Investments Trust. Dr. Frost is one of two limited partners of Frost Gamma L.P. The general partner of Frost Gamma L.P. is Frost Gamma, Inc., and the sole shareholder of Frost Gamma, Inc. is Frost-Nevada Corporation. Dr. Frost is also the sole shareholder of Frost-Nevada Corporation. The reporting person disclaims beneficial ownership of these securities, except to the extent of any pecuniary interest therein and this report shall not be deemed an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

Read SEC document
August 05, 2022 Filed Aug 8, 2022 12:05 UTC
FROST PHILLIP MD ET ALDirector · CEO & Chairman · 10% owner
PurchaseCommon Stock 700 $2.27 $1,585.50
Disclosure

SEC source: 0001209191-22-044703 · doc4.xml · nonDerivative · entry 7

FROST PHILLIP MD ET AL · CIK 0000898860 · Director · CEO & Chairman · 10% owner

Frost Gamma Investments Trust · CIK 0001380896 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 196,626,913

F1 · ownership.nature: The securities are held by Frost Gamma Investments Trust, of which Phillip Frost M.D., is the trustee. Frost Gamma L.P. is the sole and exclusive beneficiary of Frost Gamma Investments Trust. Dr. Frost is one of two limited partners of Frost Gamma L.P. The general partner of Frost Gamma L.P. is Frost Gamma, Inc., and the sole shareholder of Frost Gamma, Inc. is Frost-Nevada Corporation. Dr. Frost is also the sole shareholder of Frost-Nevada Corporation. The reporting person disclaims beneficial ownership of these securities, except to the extent of any pecuniary interest therein and this report shall not be deemed an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

Read SEC document
August 05, 2022 Filed Aug 8, 2022 12:05 UTC
FROST PHILLIP MD ET ALDirector · CEO & Chairman · 10% owner
PurchaseCommon Stock 9,869 $2.26 $22,303.94
Disclosure

SEC source: 0001209191-22-044703 · doc4.xml · nonDerivative · entry 6

FROST PHILLIP MD ET AL · CIK 0000898860 · Director · CEO & Chairman · 10% owner

Frost Gamma Investments Trust · CIK 0001380896 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 196,626,213

F1 · ownership.nature: The securities are held by Frost Gamma Investments Trust, of which Phillip Frost M.D., is the trustee. Frost Gamma L.P. is the sole and exclusive beneficiary of Frost Gamma Investments Trust. Dr. Frost is one of two limited partners of Frost Gamma L.P. The general partner of Frost Gamma L.P. is Frost Gamma, Inc., and the sole shareholder of Frost Gamma, Inc. is Frost-Nevada Corporation. Dr. Frost is also the sole shareholder of Frost-Nevada Corporation. The reporting person disclaims beneficial ownership of these securities, except to the extent of any pecuniary interest therein and this report shall not be deemed an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

Read SEC document
August 05, 2022 Filed Aug 8, 2022 12:05 UTC
FROST PHILLIP MD ET ALDirector · CEO & Chairman · 10% owner
PurchaseCommon Stock 1,600 $2.26 $3,614.40
Disclosure

SEC source: 0001209191-22-044703 · doc4.xml · nonDerivative · entry 5

FROST PHILLIP MD ET AL · CIK 0000898860 · Director · CEO & Chairman · 10% owner

Frost Gamma Investments Trust · CIK 0001380896 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 196,616,344

F1 · ownership.nature: The securities are held by Frost Gamma Investments Trust, of which Phillip Frost M.D., is the trustee. Frost Gamma L.P. is the sole and exclusive beneficiary of Frost Gamma Investments Trust. Dr. Frost is one of two limited partners of Frost Gamma L.P. The general partner of Frost Gamma L.P. is Frost Gamma, Inc., and the sole shareholder of Frost Gamma, Inc. is Frost-Nevada Corporation. Dr. Frost is also the sole shareholder of Frost-Nevada Corporation. The reporting person disclaims beneficial ownership of these securities, except to the extent of any pecuniary interest therein and this report shall not be deemed an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

Read SEC document
August 05, 2022 Filed Aug 8, 2022 12:05 UTC
FROST PHILLIP MD ET ALDirector · CEO & Chairman · 10% owner
PurchaseCommon Stock 400 $2.26 $902.00
Disclosure

SEC source: 0001209191-22-044703 · doc4.xml · nonDerivative · entry 4

FROST PHILLIP MD ET AL · CIK 0000898860 · Director · CEO & Chairman · 10% owner

Frost Gamma Investments Trust · CIK 0001380896 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 196,614,744

F1 · ownership.nature: The securities are held by Frost Gamma Investments Trust, of which Phillip Frost M.D., is the trustee. Frost Gamma L.P. is the sole and exclusive beneficiary of Frost Gamma Investments Trust. Dr. Frost is one of two limited partners of Frost Gamma L.P. The general partner of Frost Gamma L.P. is Frost Gamma, Inc., and the sole shareholder of Frost Gamma, Inc. is Frost-Nevada Corporation. Dr. Frost is also the sole shareholder of Frost-Nevada Corporation. The reporting person disclaims beneficial ownership of these securities, except to the extent of any pecuniary interest therein and this report shall not be deemed an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

Read SEC document
August 05, 2022 Filed Aug 8, 2022 12:05 UTC
FROST PHILLIP MD ET ALDirector · CEO & Chairman · 10% owner
PurchaseCommon Stock 7,350 $2.25 $16,537.50
Disclosure

SEC source: 0001209191-22-044703 · doc4.xml · nonDerivative · entry 3

FROST PHILLIP MD ET AL · CIK 0000898860 · Director · CEO & Chairman · 10% owner

Frost Gamma Investments Trust · CIK 0001380896 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 196,614,344

F1 · ownership.nature: The securities are held by Frost Gamma Investments Trust, of which Phillip Frost M.D., is the trustee. Frost Gamma L.P. is the sole and exclusive beneficiary of Frost Gamma Investments Trust. Dr. Frost is one of two limited partners of Frost Gamma L.P. The general partner of Frost Gamma L.P. is Frost Gamma, Inc., and the sole shareholder of Frost Gamma, Inc. is Frost-Nevada Corporation. Dr. Frost is also the sole shareholder of Frost-Nevada Corporation. The reporting person disclaims beneficial ownership of these securities, except to the extent of any pecuniary interest therein and this report shall not be deemed an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

Read SEC document
August 05, 2022 Filed Aug 8, 2022 12:05 UTC
FROST PHILLIP MD ET ALDirector · CEO & Chairman · 10% owner
PurchaseCommon Stock 300 $2.25 $673.50
Disclosure

SEC source: 0001209191-22-044703 · doc4.xml · nonDerivative · entry 2

FROST PHILLIP MD ET AL · CIK 0000898860 · Director · CEO & Chairman · 10% owner

Frost Gamma Investments Trust · CIK 0001380896 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 196,606,994

F1 · ownership.nature: The securities are held by Frost Gamma Investments Trust, of which Phillip Frost M.D., is the trustee. Frost Gamma L.P. is the sole and exclusive beneficiary of Frost Gamma Investments Trust. Dr. Frost is one of two limited partners of Frost Gamma L.P. The general partner of Frost Gamma L.P. is Frost Gamma, Inc., and the sole shareholder of Frost Gamma, Inc. is Frost-Nevada Corporation. Dr. Frost is also the sole shareholder of Frost-Nevada Corporation. The reporting person disclaims beneficial ownership of these securities, except to the extent of any pecuniary interest therein and this report shall not be deemed an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

Read SEC document
July 14, 2022 Filed Jul 15, 2022 21:30 UTC GrantStock Option (Right to Buy) · Derivative 30,000 $0.00 Strike: $2.69 $0.00
Disclosure

SEC source: 0001209191-22-042281 · doc4.xml · derivative · entry 1

Yu Alice Lin-Tsing · CIK 0001462564 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 30,000

Underlying: Common Stock · 30,000 shares

Expires 2032-07-13

Read SEC document
July 14, 2022 Filed Jul 15, 2022 21:29 UTC GrantStock Option (Right to Buy) · Derivative 60,000 $0.00 Strike: $2.69 $0.00
Disclosure

SEC source: 0001209191-22-042280 · doc4.xml · derivative · entry 1

PFENNIGER RICHARD C JR · CIK 0001200796 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 60,000

Underlying: Common Stock · 60,000 shares

Expires 2032-07-13

Read SEC document
July 14, 2022 Filed Jul 15, 2022 21:28 UTC GrantStock Option (Right to Buy) · Derivative 30,000 $0.00 Strike: $2.69 $0.00
Disclosure

SEC source: 0001209191-22-042279 · doc4.xml · derivative · entry 1

PAGANELLI JOHN A · CIK 0001236687 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 30,000

Underlying: Common Stock · 30,000 shares

Expires 2032-07-13

Read SEC document
July 14, 2022 Filed Jul 15, 2022 21:27 UTC GrantStock Option (Right to Buy) · Derivative 30,000 $0.00 Strike: $2.69 $0.00
Disclosure

SEC source: 0001209191-22-042278 · doc4.xml · derivative · entry 1

MEDEL ROGER MD · CIK 0001093125 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 30,000

Underlying: Common Stock · 30,000 shares

Expires 2032-07-13

Read SEC document
July 14, 2022 Filed Jul 15, 2022 21:25 UTC GrantStock Option (Right to Buy) · Derivative 30,000 $0.00 Strike: $2.69 $0.00
Disclosure

SEC source: 0001209191-22-042276 · doc4.xml · derivative · entry 1

Lachman Prem A · CIK 0001847885 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 30,000

Underlying: Common Stock · 30,000 shares

Expires 2032-07-13

Read SEC document
July 14, 2022 Filed Jul 15, 2022 21:24 UTC GrantStock Option (Right to Buy) · Derivative 30,000 $0.00 Strike: $2.69 $0.00
Disclosure

SEC source: 0001209191-22-042275 · doc4.xml · derivative · entry 1

KRASNO RICHARD M · CIK 0001215060 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 30,000

Underlying: Common Stock · 30,000 shares

Expires 2032-07-13

Read SEC document
July 14, 2022 Filed Jul 15, 2022 21:24 UTC GrantStock Option (Right to Buy) · Derivative 30,000 $0.00 Strike: $2.69 $0.00
Disclosure

SEC source: 0001209191-22-042274 · doc4.xml · derivative · entry 1

Borisy Alexis · CIK 0001319446 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 30,000

Underlying: Common Stock · 30,000 shares

Expires 2032-07-13

Read SEC document
June 22, 2022 Filed Jun 24, 2022 23:52 UTC
Nabel Gary J.Director · Chief Innovation Officer
PurchaseCommon Stock 80,000 $2.47 $197,600.00
Disclosure

SEC source: 0001209191-22-039341 · doc4.xml · nonDerivative · entry 8

Nabel Gary J. · CIK 0001867450 · Director · Chief Innovation Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · Held by Nabel Family Investments LLC

Disclosed balance after: 80,000

F3 · ownership.nature: Shares held by the Nabel Family Investments LLC, of which the Reporting Person is the manager with sole investment power and has an approximately 48% interest through the parent trust, the 2009 Nabel Family Children's Trust of which the Reporting Person has sole control, and sole investment power. The Reporting Per disclaims beneficial ownership of these securities, except to the extent of any pecuniary interest therein and this report shall not be dee admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

Read SEC document
June 22, 2022 Filed Jun 24, 2022 23:52 UTC
Nabel Gary J.Director · Chief Innovation Officer
PurchaseCommon Stock 33,777 $2.50 $84,442.50
Disclosure

SEC source: 0001209191-22-039341 · doc4.xml · nonDerivative · entry 7

Nabel Gary J. · CIK 0001867450 · Director · Chief Innovation Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · Held by the EGN 2021 TRUST

Disclosed balance after: 19,857,514

F2 · ownership.nature: Shares held by the EGN 2021 TRUST for the benefit of the Reporting Person and his descendants, and for which an independent trustee has been appointed. The Reporting Person and the independent trustee serve as investment advisors of the trust. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of any pecuniary interest therein and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

Read SEC document
June 22, 2022 Filed Jun 24, 2022 23:52 UTC
Nabel Gary J.Director · Chief Innovation Officer
PurchaseCommon Stock 15,200 $2.50 $37,962.00
Disclosure

SEC source: 0001209191-22-039341 · doc4.xml · nonDerivative · entry 6

Nabel Gary J. · CIK 0001867450 · Director · Chief Innovation Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · Held by the EGN 2021 TRUST

Disclosed balance after: 19,823,737

F2 · ownership.nature: Shares held by the EGN 2021 TRUST for the benefit of the Reporting Person and his descendants, and for which an independent trustee has been appointed. The Reporting Person and the independent trustee serve as investment advisors of the trust. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of any pecuniary interest therein and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

Read SEC document
June 22, 2022 Filed Jun 24, 2022 23:52 UTC
Nabel Gary J.Director · Chief Innovation Officer
PurchaseCommon Stock 31,023 $2.50 $77,402.39
Disclosure

SEC source: 0001209191-22-039341 · doc4.xml · nonDerivative · entry 5

Nabel Gary J. · CIK 0001867450 · Director · Chief Innovation Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · Held by the EGN 2021 TRUST

Disclosed balance after: 19,808,537

F2 · ownership.nature: Shares held by the EGN 2021 TRUST for the benefit of the Reporting Person and his descendants, and for which an independent trustee has been appointed. The Reporting Person and the independent trustee serve as investment advisors of the trust. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of any pecuniary interest therein and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

Read SEC document
June 22, 2022 Filed Jun 24, 2022 23:52 UTC
Nabel Gary J.Director · Chief Innovation Officer
PurchaseCommon Stock 13,229 $2.50 $33,072.50
Disclosure

SEC source: 0001209191-22-039341 · doc4.xml · nonDerivative · entry 4

Nabel Gary J. · CIK 0001867450 · Director · Chief Innovation Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · Held by the GJN 2021 TRUST

Disclosed balance after: 19,857,514

F1 · ownership.nature: Shares held by the GJN 2021 TRUST for the benefit of the Reporting Person's spouse and descendants, and for which the Reporting Person's spouse serves as co-trustee together with an independent trustee. The Reporting Person's spouse and the independent trustee serve as investment advisors of the trust. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of any pecuniary interest therein and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

Read SEC document
June 22, 2022 Filed Jun 24, 2022 23:52 UTC
Nabel Gary J.Director · Chief Innovation Officer
PurchaseCommon Stock 65,280 $2.50 $163,193.47
Disclosure

SEC source: 0001209191-22-039341 · doc4.xml · nonDerivative · entry 3

Nabel Gary J. · CIK 0001867450 · Director · Chief Innovation Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · Held by the GJN 2021 TRUST

Disclosed balance after: 19,844,285

F1 · ownership.nature: Shares held by the GJN 2021 TRUST for the benefit of the Reporting Person's spouse and descendants, and for which the Reporting Person's spouse serves as co-trustee together with an independent trustee. The Reporting Person's spouse and the independent trustee serve as investment advisors of the trust. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of any pecuniary interest therein and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

Read SEC document
June 22, 2022 Filed Jun 24, 2022 23:52 UTC
Nabel Gary J.Director · Chief Innovation Officer
PurchaseCommon Stock 1,491 $2.50 $3,720.05
Disclosure

SEC source: 0001209191-22-039341 · doc4.xml · nonDerivative · entry 2

Nabel Gary J. · CIK 0001867450 · Director · Chief Innovation Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · Held by the GJN 2021 TRUST

Disclosed balance after: 19,779,005

F1 · ownership.nature: Shares held by the GJN 2021 TRUST for the benefit of the Reporting Person's spouse and descendants, and for which the Reporting Person's spouse serves as co-trustee together with an independent trustee. The Reporting Person's spouse and the independent trustee serve as investment advisors of the trust. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of any pecuniary interest therein and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

Read SEC document
June 21, 2022 Filed Jun 22, 2022 10:59 UTC
FROST PHILLIP MD ET ALDirector · CEO & Chairman · 10% owner
PurchaseCommon Stock 692 $2.41 $1,667.72
Disclosure

SEC source: 0001209191-22-038619 · doc4.xml · nonDerivative · entry 8

FROST PHILLIP MD ET AL · CIK 0000898860 · Director · CEO & Chairman · 10% owner

Frost Gamma Investments Trust · CIK 0001380896 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 196,606,694

F1 · ownership.nature: The securities are held by Frost Gamma Investments Trust, of which Phillip Frost M.D., is the trustee. Frost Gamma L.P. is the sole and exclusive beneficiary of Frost Gamma Investments Trust. Dr. Frost is one of two limited partners of Frost Gamma L.P. The general partner of Frost Gamma L.P. is Frost Gamma, Inc., and the sole shareholder of Frost Gamma, Inc. is Frost-Nevada Corporation. Dr. Frost is also the sole shareholder of Frost-Nevada Corporation. The reporting person disclaims beneficial ownership of these securities, except to the extent of any pecuniary interest therein and this report shall not be deemed an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

Read SEC document
June 21, 2022 Filed Jun 22, 2022 10:59 UTC
FROST PHILLIP MD ET ALDirector · CEO & Chairman · 10% owner
PurchaseCommon Stock 7,466 $2.41 $17,955.73
Disclosure

SEC source: 0001209191-22-038619 · doc4.xml · nonDerivative · entry 7

FROST PHILLIP MD ET AL · CIK 0000898860 · Director · CEO & Chairman · 10% owner

Frost Gamma Investments Trust · CIK 0001380896 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 196,606,002

F1 · ownership.nature: The securities are held by Frost Gamma Investments Trust, of which Phillip Frost M.D., is the trustee. Frost Gamma L.P. is the sole and exclusive beneficiary of Frost Gamma Investments Trust. Dr. Frost is one of two limited partners of Frost Gamma L.P. The general partner of Frost Gamma L.P. is Frost Gamma, Inc., and the sole shareholder of Frost Gamma, Inc. is Frost-Nevada Corporation. Dr. Frost is also the sole shareholder of Frost-Nevada Corporation. The reporting person disclaims beneficial ownership of these securities, except to the extent of any pecuniary interest therein and this report shall not be deemed an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

Read SEC document
June 21, 2022 Filed Jun 22, 2022 10:59 UTC
FROST PHILLIP MD ET ALDirector · CEO & Chairman · 10% owner
PurchaseCommon Stock 68,340 $2.40 $164,016.00
Disclosure

SEC source: 0001209191-22-038619 · doc4.xml · nonDerivative · entry 6

FROST PHILLIP MD ET AL · CIK 0000898860 · Director · CEO & Chairman · 10% owner

Frost Gamma Investments Trust · CIK 0001380896 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 196,598,536

F1 · ownership.nature: The securities are held by Frost Gamma Investments Trust, of which Phillip Frost M.D., is the trustee. Frost Gamma L.P. is the sole and exclusive beneficiary of Frost Gamma Investments Trust. Dr. Frost is one of two limited partners of Frost Gamma L.P. The general partner of Frost Gamma L.P. is Frost Gamma, Inc., and the sole shareholder of Frost Gamma, Inc. is Frost-Nevada Corporation. Dr. Frost is also the sole shareholder of Frost-Nevada Corporation. The reporting person disclaims beneficial ownership of these securities, except to the extent of any pecuniary interest therein and this report shall not be deemed an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

Read SEC document
June 21, 2022 Filed Jun 22, 2022 10:59 UTC
FROST PHILLIP MD ET ALDirector · CEO & Chairman · 10% owner
PurchaseCommon Stock 40,009 $2.40 $95,821.56
Disclosure

SEC source: 0001209191-22-038619 · doc4.xml · nonDerivative · entry 5

FROST PHILLIP MD ET AL · CIK 0000898860 · Director · CEO & Chairman · 10% owner

Frost Gamma Investments Trust · CIK 0001380896 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 196,530,196

F1 · ownership.nature: The securities are held by Frost Gamma Investments Trust, of which Phillip Frost M.D., is the trustee. Frost Gamma L.P. is the sole and exclusive beneficiary of Frost Gamma Investments Trust. Dr. Frost is one of two limited partners of Frost Gamma L.P. The general partner of Frost Gamma L.P. is Frost Gamma, Inc., and the sole shareholder of Frost Gamma, Inc. is Frost-Nevada Corporation. Dr. Frost is also the sole shareholder of Frost-Nevada Corporation. The reporting person disclaims beneficial ownership of these securities, except to the extent of any pecuniary interest therein and this report shall not be deemed an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

Read SEC document
June 21, 2022 Filed Jun 22, 2022 10:59 UTC
FROST PHILLIP MD ET ALDirector · CEO & Chairman · 10% owner
PurchaseCommon Stock 49,778 $2.39 $118,969.42
Disclosure

SEC source: 0001209191-22-038619 · doc4.xml · nonDerivative · entry 4

FROST PHILLIP MD ET AL · CIK 0000898860 · Director · CEO & Chairman · 10% owner

Frost Gamma Investments Trust · CIK 0001380896 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 196,490,187

F1 · ownership.nature: The securities are held by Frost Gamma Investments Trust, of which Phillip Frost M.D., is the trustee. Frost Gamma L.P. is the sole and exclusive beneficiary of Frost Gamma Investments Trust. Dr. Frost is one of two limited partners of Frost Gamma L.P. The general partner of Frost Gamma L.P. is Frost Gamma, Inc., and the sole shareholder of Frost Gamma, Inc. is Frost-Nevada Corporation. Dr. Frost is also the sole shareholder of Frost-Nevada Corporation. The reporting person disclaims beneficial ownership of these securities, except to the extent of any pecuniary interest therein and this report shall not be deemed an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

Read SEC document
June 21, 2022 Filed Jun 22, 2022 10:59 UTC
FROST PHILLIP MD ET ALDirector · CEO & Chairman · 10% owner
PurchaseCommon Stock 4,000 $2.39 $9,556.00
Disclosure

SEC source: 0001209191-22-038619 · doc4.xml · nonDerivative · entry 3

FROST PHILLIP MD ET AL · CIK 0000898860 · Director · CEO & Chairman · 10% owner

Frost Gamma Investments Trust · CIK 0001380896 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 196,440,409

F1 · ownership.nature: The securities are held by Frost Gamma Investments Trust, of which Phillip Frost M.D., is the trustee. Frost Gamma L.P. is the sole and exclusive beneficiary of Frost Gamma Investments Trust. Dr. Frost is one of two limited partners of Frost Gamma L.P. The general partner of Frost Gamma L.P. is Frost Gamma, Inc., and the sole shareholder of Frost Gamma, Inc. is Frost-Nevada Corporation. Dr. Frost is also the sole shareholder of Frost-Nevada Corporation. The reporting person disclaims beneficial ownership of these securities, except to the extent of any pecuniary interest therein and this report shall not be deemed an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

Read SEC document
June 21, 2022 Filed Jun 22, 2022 10:59 UTC
FROST PHILLIP MD ET ALDirector · CEO & Chairman · 10% owner
PurchaseCommon Stock 29,715 $2.39 $70,870.28
Disclosure

SEC source: 0001209191-22-038619 · doc4.xml · nonDerivative · entry 2

FROST PHILLIP MD ET AL · CIK 0000898860 · Director · CEO & Chairman · 10% owner

Frost Gamma Investments Trust · CIK 0001380896 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 196,436,409

F1 · ownership.nature: The securities are held by Frost Gamma Investments Trust, of which Phillip Frost M.D., is the trustee. Frost Gamma L.P. is the sole and exclusive beneficiary of Frost Gamma Investments Trust. Dr. Frost is one of two limited partners of Frost Gamma L.P. The general partner of Frost Gamma L.P. is Frost Gamma, Inc., and the sole shareholder of Frost Gamma, Inc. is Frost-Nevada Corporation. Dr. Frost is also the sole shareholder of Frost-Nevada Corporation. The reporting person disclaims beneficial ownership of these securities, except to the extent of any pecuniary interest therein and this report shall not be deemed an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

Read SEC document
June 16, 2022 Filed Jun 17, 2022 12:11 UTC
FROST PHILLIP MD ET ALDirector · CEO & Chairman · 10% owner
PurchaseCommon Stock 400 $2.35 $940.00
Disclosure

SEC source: 0001209191-22-037687 · doc4.xml · nonDerivative · entry 14

FROST PHILLIP MD ET AL · CIK 0000898860 · Director · CEO & Chairman · 10% owner

Frost Gamma Investments Trust · CIK 0001380896 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 196,406,694

F1 · ownership.nature: The securities are held by Frost Gamma Investments Trust, of which Phillip Frost M.D., is the trustee. Frost Gamma L.P. is the sole and exclusive beneficiary of Frost Gamma Investments Trust. Dr. Frost is one of two limited partners of Frost Gamma L.P. The general partner of Frost Gamma L.P. is Frost Gamma, Inc., and the sole shareholder of Frost Gamma, Inc. is Frost-Nevada Corporation. Dr. Frost is also the sole shareholder of Frost-Nevada Corporation. The reporting person disclaims beneficial ownership of these securities, except to the extent of any pecuniary interest therein and this report shall not be deemed an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

Read SEC document
June 16, 2022 Filed Jun 17, 2022 12:11 UTC
FROST PHILLIP MD ET ALDirector · CEO & Chairman · 10% owner
PurchaseCommon Stock 9,551 $2.35 $22,397.10
Disclosure

SEC source: 0001209191-22-037687 · doc4.xml · nonDerivative · entry 13

FROST PHILLIP MD ET AL · CIK 0000898860 · Director · CEO & Chairman · 10% owner

Frost Gamma Investments Trust · CIK 0001380896 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 196,406,294

F1 · ownership.nature: The securities are held by Frost Gamma Investments Trust, of which Phillip Frost M.D., is the trustee. Frost Gamma L.P. is the sole and exclusive beneficiary of Frost Gamma Investments Trust. Dr. Frost is one of two limited partners of Frost Gamma L.P. The general partner of Frost Gamma L.P. is Frost Gamma, Inc., and the sole shareholder of Frost Gamma, Inc. is Frost-Nevada Corporation. Dr. Frost is also the sole shareholder of Frost-Nevada Corporation. The reporting person disclaims beneficial ownership of these securities, except to the extent of any pecuniary interest therein and this report shall not be deemed an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

Read SEC document
June 16, 2022 Filed Jun 17, 2022 12:11 UTC
FROST PHILLIP MD ET ALDirector · CEO & Chairman · 10% owner
PurchaseCommon Stock 4,100 $2.34 $9,573.50
Disclosure

SEC source: 0001209191-22-037687 · doc4.xml · nonDerivative · entry 12

FROST PHILLIP MD ET AL · CIK 0000898860 · Director · CEO & Chairman · 10% owner

Frost Gamma Investments Trust · CIK 0001380896 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 196,396,743

F1 · ownership.nature: The securities are held by Frost Gamma Investments Trust, of which Phillip Frost M.D., is the trustee. Frost Gamma L.P. is the sole and exclusive beneficiary of Frost Gamma Investments Trust. Dr. Frost is one of two limited partners of Frost Gamma L.P. The general partner of Frost Gamma L.P. is Frost Gamma, Inc., and the sole shareholder of Frost Gamma, Inc. is Frost-Nevada Corporation. Dr. Frost is also the sole shareholder of Frost-Nevada Corporation. The reporting person disclaims beneficial ownership of these securities, except to the extent of any pecuniary interest therein and this report shall not be deemed an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

Read SEC document
June 16, 2022 Filed Jun 17, 2022 12:11 UTC
FROST PHILLIP MD ET ALDirector · CEO & Chairman · 10% owner
PurchaseCommon Stock 100 $2.33 $233.25
Disclosure

SEC source: 0001209191-22-037687 · doc4.xml · nonDerivative · entry 11

FROST PHILLIP MD ET AL · CIK 0000898860 · Director · CEO & Chairman · 10% owner

Frost Gamma Investments Trust · CIK 0001380896 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 196,392,643

F1 · ownership.nature: The securities are held by Frost Gamma Investments Trust, of which Phillip Frost M.D., is the trustee. Frost Gamma L.P. is the sole and exclusive beneficiary of Frost Gamma Investments Trust. Dr. Frost is one of two limited partners of Frost Gamma L.P. The general partner of Frost Gamma L.P. is Frost Gamma, Inc., and the sole shareholder of Frost Gamma, Inc. is Frost-Nevada Corporation. Dr. Frost is also the sole shareholder of Frost-Nevada Corporation. The reporting person disclaims beneficial ownership of these securities, except to the extent of any pecuniary interest therein and this report shall not be deemed an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

Read SEC document
June 16, 2022 Filed Jun 17, 2022 12:11 UTC
FROST PHILLIP MD ET ALDirector · CEO & Chairman · 10% owner
PurchaseCommon Stock 300 $2.33 $699.03
Disclosure

SEC source: 0001209191-22-037687 · doc4.xml · nonDerivative · entry 10

FROST PHILLIP MD ET AL · CIK 0000898860 · Director · CEO & Chairman · 10% owner

Frost Gamma Investments Trust · CIK 0001380896 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 196,392,543

F1 · ownership.nature: The securities are held by Frost Gamma Investments Trust, of which Phillip Frost M.D., is the trustee. Frost Gamma L.P. is the sole and exclusive beneficiary of Frost Gamma Investments Trust. Dr. Frost is one of two limited partners of Frost Gamma L.P. The general partner of Frost Gamma L.P. is Frost Gamma, Inc., and the sole shareholder of Frost Gamma, Inc. is Frost-Nevada Corporation. Dr. Frost is also the sole shareholder of Frost-Nevada Corporation. The reporting person disclaims beneficial ownership of these securities, except to the extent of any pecuniary interest therein and this report shall not be deemed an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

Read SEC document
June 16, 2022 Filed Jun 17, 2022 12:11 UTC
FROST PHILLIP MD ET ALDirector · CEO & Chairman · 10% owner
PurchaseCommon Stock 28,614 $2.33 $66,527.55
Disclosure

SEC source: 0001209191-22-037687 · doc4.xml · nonDerivative · entry 9

FROST PHILLIP MD ET AL · CIK 0000898860 · Director · CEO & Chairman · 10% owner

Frost Gamma Investments Trust · CIK 0001380896 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 196,392,243

F1 · ownership.nature: The securities are held by Frost Gamma Investments Trust, of which Phillip Frost M.D., is the trustee. Frost Gamma L.P. is the sole and exclusive beneficiary of Frost Gamma Investments Trust. Dr. Frost is one of two limited partners of Frost Gamma L.P. The general partner of Frost Gamma L.P. is Frost Gamma, Inc., and the sole shareholder of Frost Gamma, Inc. is Frost-Nevada Corporation. Dr. Frost is also the sole shareholder of Frost-Nevada Corporation. The reporting person disclaims beneficial ownership of these securities, except to the extent of any pecuniary interest therein and this report shall not be deemed an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

Read SEC document
June 16, 2022 Filed Jun 17, 2022 12:11 UTC
FROST PHILLIP MD ET ALDirector · CEO & Chairman · 10% owner
PurchaseCommon Stock 14,549 $2.32 $33,680.94
Disclosure

SEC source: 0001209191-22-037687 · doc4.xml · nonDerivative · entry 8

FROST PHILLIP MD ET AL · CIK 0000898860 · Director · CEO & Chairman · 10% owner

Frost Gamma Investments Trust · CIK 0001380896 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 196,363,629

F1 · ownership.nature: The securities are held by Frost Gamma Investments Trust, of which Phillip Frost M.D., is the trustee. Frost Gamma L.P. is the sole and exclusive beneficiary of Frost Gamma Investments Trust. Dr. Frost is one of two limited partners of Frost Gamma L.P. The general partner of Frost Gamma L.P. is Frost Gamma, Inc., and the sole shareholder of Frost Gamma, Inc. is Frost-Nevada Corporation. Dr. Frost is also the sole shareholder of Frost-Nevada Corporation. The reporting person disclaims beneficial ownership of these securities, except to the extent of any pecuniary interest therein and this report shall not be deemed an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.